Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY - Get Free Report)'s stock price reached a new 52-week high during trading on Wednesday . The company traded as high as $30.74 and last traded at $29.71, with a volume of 155066 shares. The stock had previously closed at $29.73.
Chugai Pharmaceutical Trading Down 0.1 %
The company has a market cap of $97.78 billion, a price-to-earnings ratio of 38.58 and a beta of 0.80. The firm has a 50-day moving average price of $24.00 and a 200 day moving average price of $22.90.
Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last released its earnings results on Thursday, January 30th. The company reported $0.18 earnings per share for the quarter. Chugai Pharmaceutical had a net margin of 33.07% and a return on equity of 21.53%. Research analysts anticipate that Chugai Pharmaceutical Co., Ltd. will post 0.74 earnings per share for the current fiscal year.
Chugai Pharmaceutical Company Profile
(
Get Free Report)
Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Chugai Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chugai Pharmaceutical wasn't on the list.
While Chugai Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
